What is malignant rhabdoid tumour of the kidney?
Malignant rhabdoid tumour of the kidney, often shortened to rhabdoid tumour of the kidney (RTK), is a very rare and aggressive childhood cancer. It makes up only about 2% of kidney tumours in children (Brok et al., 2016).
It mainly affects babies and toddlers. Most children are diagnosed before the age of 2, and the average age is around one year (Tomlinson et al., 2005).
The name comes from the look of the tumour cells under the microscope. They resemble immature muscle cells (rhabdomyoblasts), but the tumour is not a muscle tumour.
Almost all rhabdoid tumours share one key change: loss of a gene called SMARCB1 (also known as INI1 or hSNF5). In some children this change is present from birth in every cell, which is called rhabdoid tumour predisposition syndrome (Fruhwald et al., 2021).
The same type of tumour can also occur in the brain, where it is called atypical teratoid/rhabdoid tumour (AT/RT), and in soft tissues or the liver. Treatment is intensive and combines surgery, chemotherapy and radiotherapy.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Highly malignant embryonal tumour of the kidney |
| How common | About 2% of childhood kidney tumours |
| Typical age | Most under 2 years; median around 1 year |
| Key gene change | Loss of SMARCB1 (INI1); rarely SMARCA4 |
| Inherited form | Germline SMARCB1 change in about a quarter to a third of children |
| Common symptoms | Tummy lump, blood in the urine, fever, high blood pressure |
| Typical spread | Lungs, lymph nodes, liver, bone and brain |
| Main treatment | Nephrectomy, intensive chemotherapy and radiotherapy |
| Outlook | Serious; about a quarter to a third survive long term, better in older children |
2. Where rhabdoid tumours occur
| Site | Name | Notes |
|---|---|---|
| Kidney | Rhabdoid tumour of the kidney (RTK) | The site where rhabdoid tumour was first described |
| Brain and spinal cord | Atypical teratoid/rhabdoid tumour (AT/RT) | Most common in children under 3 |
| Soft tissues and other organs | Extrarenal extracranial rhabdoid tumour | Neck, trunk, limbs, liver and other sites |
Some children have rhabdoid tumours in more than one place, for example in the kidney and the brain at the same time. This is much more likely when there is an inherited SMARCB1 change (Brennan et al., 2013).
3. Causes and risk factors
The tumour develops when both copies of the SMARCB1 gene stop working in a kidney cell. SMARCB1 normally helps control which genes are switched on and off. Without it, cells can grow in an uncontrolled way.
Rhabdoid tumours have very few other gene changes, which makes them one of the “simplest” cancers genetically.
| Risk factor | Explanation |
|---|---|
| Germline SMARCB1 change | Rhabdoid tumour predisposition syndrome type 1 (RTPS1); often a new change not found in either parent |
| Germline SMARCA4 change | Rhabdoid tumour predisposition syndrome type 2 (RTPS2); rare |
| Very young age | Germline changes are found more often in babies under 6 months |
| Multiple tumours | Tumours in the kidney and brain together strongly suggest a germline change |
No environmental cause is known. Nothing parents did during pregnancy or afterwards causes the tumour.
Genetic testing
Because of the link with rhabdoid tumour predisposition syndrome, every child with RTK should be offered genetic counselling and a blood test for germline SMARCB1 changes (Fruhwald et al., 2021).
| If a germline change is found | What it means |
|---|---|
| For the child | Regular brain and abdominal scans to look for new tumours |
| For parents | Testing to see if a parent carries the change, sometimes without being affected |
| For brothers and sisters | Testing and, if positive, surveillance in early childhood |
| For future pregnancies | Genetic counselling about the chance of recurrence, including rare parental mosaicism |
4. How does it look
On scans
| Feature | Description |
|---|---|
| Size | Usually large, often 8-10 cm or more |
| Position | Often centred in the middle of the kidney, near the renal sinus |
| Inside the tumour | Areas of bleeding and dead tissue (necrosis); sometimes calcification |
| Typical clue | A crescent of fluid or blood under the kidney capsule (subcapsular collection) |
| Spread | Lymph nodes, lungs, liver and sometimes bone |
These features can suggest rhabdoid tumour, but scans cannot reliably tell it apart from Wilms tumour or other childhood kidney tumours. An MRI of the brain is done at diagnosis to look for a brain tumour.
To the surgeon and pathologist
When the kidney is removed, the tumour usually looks like a soft, pale-tan, poorly defined mass. It often has areas of bleeding and necrosis and tends to invade the surrounding kidney and blood vessels.
Under the microscope
| Feature | Description |
|---|---|
| Cells | Sheets of large, loosely joined cells |
| Nuclei | Round, open nuclei with a large, prominent nucleolus |
| Cytoplasm | Pink, glassy “inclusions” that push the nucleus to the side (the rhabdoid look) |
| Key stain | Loss of INI1 (SMARCB1) protein in the tumour cells, while normal cells keep it |
| Other stains | Often positive for vimentin and cytokeratin in patches |
Loss of INI1 staining is the most important test. It separates rhabdoid tumour from other tumours with a similar appearance (Weeks et al., 1991).
Visible signs
Parents usually notice a swollen tummy or feel a hard lump in one side of the abdomen. A baby may look pale, unwell or irritable, and may feed poorly.
5. Symptoms
Common symptoms
- A lump or swelling in the abdomen
- Blood in the urine, making it pink, red or brown
- Fever without an obvious infection
- Tummy pain or discomfort
- Poor feeding, vomiting or weight loss
- Tiredness or paleness from anaemia
Symptoms linked to the tumour’s chemicals
| Problem | Why it happens | Signs |
|---|---|---|
| High blood pressure | The tumour can raise renin levels | Irritability, headaches, rarely heart strain |
| High blood calcium (hypercalcaemia) | The tumour can release parathyroid hormone-related protein | Constipation, vomiting, drowsiness, passing a lot of urine |
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Cough or fast breathing, though often no symptoms |
| Brain (spread or a separate AT/RT) | Vomiting, a bulging soft spot, large head, unsteadiness, seizures, drowsiness |
| Liver | Enlarged upper abdomen |
| Bone | Bone pain or reluctance to move a limb |
When to seek medical advice
See a doctor promptly if your child has a lump or swelling in the tummy, blood in the urine, or is unusually pale and unwell.
Seek urgent help for repeated vomiting, a seizure, unusual drowsiness or a rapidly growing tummy.
6. Diagnosis
| Test | Purpose |
|---|---|
| Ultrasound | First scan; shows a kidney mass |
| CT or MRI of the abdomen | Size of the tumour, lymph nodes and blood vessels |
| CT of the chest | Looks for lung spread |
| MRI of the brain and spine | Looks for spread or a separate AT/RT |
| Bone scan or PET-CT | Sometimes used to look for bone spread |
| Blood tests | Blood count, kidney function, calcium |
| Biopsy or nephrectomy | Confirms the diagnosis, with INI1 staining |
| Germline genetic test | Blood test for SMARCB1 or SMARCA4 changes |
Staging
Rhabdoid tumour of the kidney uses the same staging as other childhood kidney tumours.
| Stage | Description |
|---|---|
| Stage I | Confined to the kidney and completely removed |
| Stage II | Spread beyond the kidney but completely removed |
| Stage III | Tumour left in the abdomen, lymph node spread or tumour spill |
| Stage IV | Spread to distant organs, such as lungs, liver, bone or brain |
Many children are diagnosed at stage III or IV.
Conditions that can look similar
| Condition | How it differs |
|---|---|
| Wilms tumour | The most common childhood kidney cancer; INI1 retained |
| Congenital mesoblastic nephroma | Babies under 6 months; much better outlook; INI1 retained |
| Clear cell sarcoma of the kidney | Young children; BCOR changes; INI1 retained |
| Neuroblastoma | Usually arises from the adrenal gland; raised urine catecholamines |
| Renal medullary carcinoma | Teenagers and young adults with sickle cell trait; also loses INI1 |
7. Treatment
Children are treated at a specialist children’s cancer centre within national or international protocols, such as the SIOP-RTSG UMBRELLA protocol in Europe and Children’s Oncology Group (COG) studies in North America (van den Heuvel-Eibrink et al., 2017; Geller et al., 2025).
Treatment usually combines three parts.
Surgery
The affected kidney is removed in an operation called a nephrectomy. Lymph nodes are sampled for staging.
| Approach | Description |
|---|---|
| Surgery first | Common when the tumour can be removed safely; gives tissue for diagnosis |
| Chemotherapy first | Used when the tumour is very large or has spread, to shrink it before surgery |
| Removing metastases | Sometimes considered for remaining lung or liver deposits |
Removing the tumour without breaking it open is important, because spill raises the stage.
Chemotherapy
Intensive chemotherapy is given to all children. Regimens alternate several drugs every few weeks.
| Typical drugs | Notes |
|---|---|
| Vincristine, doxorubicin, cyclophosphamide | Backbone of most regimens |
| Carboplatin and etoposide | Alternated with the above in COG studies |
| Ifosfamide | Used in European soft-tissue sarcoma style regimens |
| High-dose chemotherapy with stem cell rescue | Used in some centres, mainly for selected children |
European groups have tested dose-compressed schedules, where cycles are given closer together to increase intensity (Enault et al., 2022).
Radiotherapy
| Situation | Radiotherapy |
|---|---|
| Kidney area (flank) | Given to most children after surgery |
| Whole abdomen | When there was tumour spill or spread inside the abdomen |
| Lungs or other metastases | When there is distant spread |
| Very young babies | Doses and fields may be reduced to limit long-term effects |
Newer treatments
Because rhabdoid tumours depend on a protein called EZH2 when SMARCB1 is lost, EZH2 inhibitors such as tazemetostat are being studied in clinical trials. Other approaches under study include immunotherapy and drugs targeting cell-cycle proteins. Families may be offered a clinical trial, especially if the tumour comes back.
Side effects
| Treatment | Possible side effects |
|---|---|
| Chemotherapy | Infections, hair loss, sickness, mouth sores, low blood counts |
| Doxorubicin | Possible heart damage; heart scans during and after treatment |
| Cyclophosphamide and ifosfamide | Effects on fertility, kidneys and bladder |
| Carboplatin | Hearing loss; hearing tests are done |
| Radiotherapy | Effects on growth of the spine and muscles, bowel and remaining kidney |
8. Outlook (prognosis)
Rhabdoid tumour of the kidney is one of the most serious childhood kidney cancers, but outcomes have improved with modern treatment.
| Group | Approximate outlook |
|---|---|
| All children (NWTS studies) | About 23% alive at 4 years (Tomlinson et al., 2005) |
| Modern European and COG studies | Roughly a third survive without the tumour returning (Brennan et al., 2016; Geller et al., 2025) |
| Older children (2 years and over) | Clearly better, around 40% or more |
| Babies under 6 months | Poorest outlook |
| Stage I and II | Better; many children are cured |
| Stage III-IV or brain involvement | Poorer |
Most relapses happen within the first year after diagnosis, often during or soon after treatment. Children who stay well for two years after treatment have a much lower chance of the tumour coming back.
9. Follow-up and long-term effects
| Follow-up | Purpose |
|---|---|
| Scans of the chest and abdomen | Detect relapse early, most often in the first 2 years |
| Brain MRI | Especially for children with a germline change |
| Heart scans | After doxorubicin |
| Hearing tests | After carboplatin |
| Kidney function and blood pressure | Monitor the remaining kidney |
| Growth, development and puberty | Especially after radiotherapy and in babies treated very young |
Children with rhabdoid tumour predisposition syndrome need a long-term surveillance plan with regular brain and abdominal imaging, usually until around age 5 (Fruhwald et al., 2021).
10. Living with rhabdoid tumour of the kidney
- Ask for a named key worker or specialist nurse
- Report fever immediately during chemotherapy
- Ask about genetic counselling for the whole family
- Protect the remaining kidney by keeping your child well hydrated and avoiding anti-inflammatory painkillers unless advised
- Use play specialists and psychology support to help young children and siblings cope
- Look after yourself: parents of very young children with cancer often need practical and emotional support
- Keep a treatment summary of chemotherapy doses and radiotherapy for future doctors
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is rhabdoid tumour the same as Wilms tumour? | No. It is a different and more aggressive kidney cancer |
| Is it inherited? | Sometimes. About a quarter to a third of children have a germline SMARCB1 change |
| Why is a brain scan needed? | A separate rhabdoid tumour can occur in the brain |
| Can my child live with one kidney? | Yes. One healthy kidney is enough for normal life |
| Will brothers and sisters be tested? | If your child has a germline change, testing is usually offered |
| Are there new treatments? | EZH2 inhibitors and other targeted drugs are being studied in trials |
12. Questions to ask your care team
- What stage is my child’s tumour?
- Has a germline genetic test been done, and what does it mean for our family?
- Which chemotherapy and radiotherapy will my child have?
- Is a clinical trial available?
- What long-term effects should we watch for?
- How long will follow-up scans continue?
Resources
- Brennan, B., Stiller, C. and Bourdeaut, F. (2013) ‘Extracranial rhabdoid tumours: what we have learned so far and future directions’, The Lancet Oncology, 14(8), pp. e329-e336.
- Brennan, B. et al. (2016) ‘Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005′, European Journal of Cancer, 60, pp. 69-82.
- Brok, J. et al. (2016) ‘Biology and treatment of renal tumours in childhood’, European Journal of Cancer, 68, pp. 179-195.
- Enault, M. et al. (2022) ‘Extracranial rhabdoid tumours: results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations’, European Journal of Cancer, 161, pp. 64-78.
- Fruhwald, M.C. et al. (2021) ‘Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group’, Familial Cancer, 20(4), pp. 305-316.
- Geller, J.I. et al. (2025) ‘Rhabdoid tumor of the kidney and soft tissues: results from National Wilms Tumor Study-5 and Children’s Oncology Group Study AREN0321’, Pediatric Blood and Cancer, 72(3), e31490.
- Tomlinson, G.E. et al. (2005) ‘Rhabdoid tumor of the kidney in the National Wilms’ Tumor Study: age at diagnosis as a prognostic factor’, Journal of Clinical Oncology, 23(30), pp. 7641-7645.
- van den Heuvel-Eibrink, M.M. et al. (2017) ‘Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol’, Nature Reviews Urology, 14(12), pp. 743-752.
- Weeks, D.A. et al. (1991) ‘Renal neoplasms mimicking rhabdoid tumor of kidney: a report from the National Wilms’ Tumor Study Pathology Center’, American Journal of Surgical Pathology, 15(11), pp. 1042-1054.
- National Cancer Institute (2026) Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.